Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

negativeNegative

AI Analysis

Summary

A Novartis and Bristol Myers Squibb autoimmune CAR-T study has been halted due to safety concerns, prompting industry discussion about more cautious approaches to manufacturing, enrollment, and side effect management.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

study halted

Importance:6/10

Sentiment:

-0.70

CAR-Tautoimmunesafetystudy haltclinical trial

Related Companies

$NVS $BMY

Read the original article

Published by BioPharma Dive on September 2, 2026 4:32 PM

Read Original